These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24285578)

  • 1. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
    Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
    Menhofer MH; Bartel D; Liebl J; Kubisch R; Busse J; Wagner E; Müller R; Vollmar AM; Zahler S
    Cardiovasc Res; 2014 Nov; 104(2):303-14. PubMed ID: 25239826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
    Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
    Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
    Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
    Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
    Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
    J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
    Gu Y; Scheuer C; Feng D; Menger MD; Laschke MW
    Anticancer Drugs; 2013 Sep; 24(8):781-91. PubMed ID: 23744558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    de Aguiar RB; Parise CB; Souza CR; Braggion C; Quintilio W; Moro AM; Navarro Marques FL; Buchpiguel CA; Chammas R; de Moraes JZ
    Cancer Lett; 2016 Feb; 371(2):151-60. PubMed ID: 26655277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
    Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
    Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
    Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
    BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
    Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
    Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
    Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
    Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.